Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.34 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15224289 | 0.85 | PNMT (0.47) | PNMTDRD2DRD4DRD3NPC1 | |
| SCHEMBL2328093 | 0.83 | PNMT (0.58) | PNMTDRD2DRD4DRD3NPC1 | |
| SCHEMBL252161 | 0.83 | PNMT (0.62) | PNMTDRD2DRD4DRD3NPC1 | |
| SCHEMBL27795073 | 0.82 | PNMT (0.47) | PNMTDRD2DRD4DRD3NPC1 | |
| SCHEMBL10775945 | 0.82 | PNMT (0.57) | PNMTDRD2DRD4DRD3NPC1 | |
| Bromide SCHEMBL27762439 | 0.81 | PNMT (0.60) | PNMTDRD2DRD4DRD3NPC1 | |
| SCHEMBL633763 | 0.80 | PNMT (0.68) | PNMTDRD2DRD4DRD3NPC1 | |
| SCHEMBL30606684 | 0.80 | PNMT (0.68) | PNMTDRD2DRD4DRD3NPC1 | |
| SCHEMBL263229 | 0.80 | PNMT (0.68) | PNMTDRD2DRD4DRD3NPC1 | |
| SCHEMBL4989855 | 0.80 | PNMT (0.68) | PNMTDRD2DRD4DRD3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1070 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084734-A | Preparation method of O- [2- [ [ tert-butoxycarbonyl ] amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine | 成都海杰亚医药科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| WO-2023183908-A1 | TYK2 INHIBITOR SYNTHESIS AND INTERMEDIATES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2023-09-28 | — | — | WO | claimed |
| CN-115611933-A | Process for preparing arginase inhibitors and synthetic intermediates thereof | 因赛特公司 | 2023-01-17 | — | — | CN | claimed |
| WO-2022016195-A1 | PROCESSES FOR THE PREPARATION OF ARGINASE INHIBITORS AND THEIR SYNTHETIC INTERMEDIATES | INCYTE CORPORATION (US) | 2022-01-20 | — | — | WO | claimed |
| CN-109354600-B | Preparation method of taurine modified novel Alaska cod multifunctional peptide | 浙江海洋大学 | 2021-08-10 | — | — | CN | claimed |
| CN-109354600-A | A kind of preparation method of the novel Alaska pollock multifunctional polypeptide of taurine modification | 浙江海洋大学 | 2019-02-19 | — | — | CN | claimed |
| CN-104607163-B | A kind of micro- chiral adjusting cellulose chromatography stationary phase, preparation method and applications | 北京迪马欧泰科技发展中心 | 2018-05-15 | — | — | CN | claimed |
| WO-2013036684-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC (US) | 2013-03-14 | — | — | WO | claimed |
| WO-2013036665-A1 | COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | WO | claimed |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | claimed |
| US-20130060019-A1 | Compounds for Use in Treating Neurodegenerative Disorders, Synthesis Thereof, and Intermediates Thereto | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | claimed |
| EP-2542085-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | Satori Pharmaceuticals, Inc. (US) | 2013-01-09 | — | — | EP | claimed |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | claimed |
| WO-2011109657-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| EP-2283063-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | Intezyne Technologies Inc. (US) | 2011-02-16 | — | — | EP | claimed |
| US-20090286938-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-19 | — | — | US | claimed |
| WO-2009134984-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | INTEZYNE TECHNOLGIES INC. (US) | 2009-11-05 | — | — | WO | claimed |
| US-7612153-B2 | conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-03 | — | — | US | claimed |
| US-5608104-A | QUICK ANALYSIS OF PYRETHROID COMPOUNDS WITH ANTIBODIES | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-03-04 | — | — | US | claimed |
| EP-0645628-A1 | Immunological detection method of pyrethroid compound, haptenic compound, intermediate for the haptenic compound, immunogen and antibody | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1995-03-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286938-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS FROM DIFLUOROACETATE AMMONIUM SALTS | PFAS, GFPT1, PFKFB4 | PNMT 1930/4885DRD2 3318/4885DRD4 1782/4885 |
| US-20130060019-A1 | Compounds for Use in Treating Neurodegenerative Disorders, Synthesis Thereof, and Intermediates Thereto | SNCA, HTT, PARK7 | PNMT 865/4885DRD2 2295/4885DRD4 2721/4885 |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | PNMT 452/4885DRD2 2308/4885DRD4 2059/4885 |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, ACHE | PNMT 50/4885DRD2 2388/4885DRD4 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.